Ultragenyx (RARE) Shares Plunge 45% Following Critical Drug Trial Failure
Key Takeaways Shares of Ultragenyx plummeted 45% during after-hours trading following apazunersen’s Phase 3 trial failure in treating Angelman syndrome The experimental treatment failed to achieve its primary goal and critical secondary measures in the […]
